Skip to main content
. Author manuscript; available in PMC: 2014 May 2.
Published in final edited form as: Sci Transl Med. 2011 Sep 28;3(102):102ra94. doi: 10.1126/scitranslmed.3002069

Fig. 9.

Fig. 9

Improved clinical and histological outcomes by blocking IL-15R/IL-15. (A to C) Decreased incidence of symptoms (A), improved weight gain (B), and better survival (C) of RRV-infected mice receiving anti–IL-15R/IL-15 antibodies (red) (n = 7) compared to control mice not receiving antibody (blue) (RRV only; n = 7). (D) H&E staining of longitudinal sections of extrahepatic bile ducts shows lumenal obstruction in control mice (RRV only), whereas antibody-injected infected mice had patent bile ducts with an intact epithelial lining despite RRV infection. Asterisks depict obstructed (left) or patent (right) bile duct lumens.